3
Announcements
Trials
Browse
Landscape
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
53
Neoplasms
36
Lung Neoplasms
25
Colorectal Neoplasms
23
Prostatic Neoplasms
17
Uterine Cervical Neoplasms
14
Motor Activity
13
Colonic Neoplasms
11
Carcinoma, Non-Small-Cell Lung
10
Rectal Neoplasms
9
Anxiety Disorders
9
Urinary Bladder Neoplasms
8
Pancreatic Neoplasms
8
Obesity
8
Melanoma
8
Depression
8
Lymphoma
7
Hematologic Neoplasms
7
Endometrial Neoplasms
7
Vulvar Neoplasms
6
Ovarian Neoplasms
6
Head and Neck Neoplasms
6
Breast Carcinoma In Situ
6
Sarcoma
5
Pain
5
Hematopoietic and Lymphatic System Neoplasm
5
Triple Negative Breast Neoplasms
4
Stomach Neoplasms
4
Papillomavirus Infections
4
Neoplasm Metastasis
4
Interventions
Sorafenib
131
lenvatinib
115
Bevacizumab
88
Radiosurgery
69
atezolizumab
55
sintilimab
54
Nivolumab
51
durvalumab
43
Hepatectomy
43
Fluorouracil
42
apatinib
41
Oxaliplatin
41
camrelizumab
38
Radiofrequency Ablation
38
pembrolizumab
36
Radiotherapy
36
tislelizumab
35
Leucovorin
31
Magnetic Resonance Spectroscopy
30
Immune Checkpoint Inhibitors
28
Doxorubicin
28
Folfox protocol
26
tremelimumab
25
regorafenib
25
Cisplatin
20
spartalizumab
19
donafenib
19
Gemcitabine
19
Cyclophosphamide
19
toripalimab
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Hepatocellular
×
Methods
×
Clear all
NCT07120750
2025-08-13
PRTRAS 001
Shenzhen Third People's Hospital
Not yet recruiting
332 enrolled